Clinical trials: Non-Small Cell Lung
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Carcinoma, Non-Small Cell Lung
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
- Trial name
- NCT00457392
- Testing
- erlotinib, sunitinib
- Where
- 204 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose…
- Trial name
- SELECT-2 (NCT01750281)
- Testing
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2
- Where
- 68 sites in United States, Brazil and 6 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Adenocarcinoma of Lung
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period
- Trial name
- NCT03676192
- Testing
- CT-P16, Avastin
- Where
- South Korea
- Volunteers
- 689 people
- Sponsor
- Celltrion
Non-Small-Cell Lung Cancer
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.
- Trial name
- CheckMate 568 (NCT02659059)
- Testing
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Where
- 32 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- Bristol-Myers Squibb
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03737994
- Testing
- Alectinib, Brigatinib, Carboplatin
- Where
- 491 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and…
- Trial name
- NCT00732303
- Testing
- Pemetrexed, Radiation Therapy
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoosier Cancer Research Network
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Non-small Cell Lung Cancer
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to define the safety and tolerability of this drug combination. The study will also define the response rate of patients with advanced and unresectable NSCLC.
- Trial name
- NCT02523469
- Testing
- ALT-803, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- Medical University of South Carolina
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This 4 arm study in patients with advanced Stage IIIb/IV non-small cell cancer (NSCLC) who failed at least one standard chemotherapy regimen will determine the proportion of patients with progression-free survival at 12 weeks…
- Trial name
- NCT00760929
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients
Primary Objectives: To compare the effectiveness of an interactive voice response (IVR) telephone triage/feedback system versus an interactive voice response telephone system with assessment only in monitoring and managing…
- Trial name
- NCT00423436
- Testing
- Questionnaire, Interactive Voice Response Telephone System, IVR Plus Triage
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00976677
- Testing
- erlotinib hydrochloride, paclitaxel, carboplatin
- Where
- 108 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00323869
- Testing
- Bevacizumab, Gemcitabine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Non-Small-Cell Lung Carcinoma
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in…
- Trial name
- NCT00915005
- Testing
- Photon Therapy, Proton Therapy, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 275 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00118131
- Testing
- cisplatin, docetaxel
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.